Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782490 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
A Phase 2 study of Multiple Sclerosis Spasticity, sponsored by Celgene.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06782490 is a Phase 2 study of Multiple Sclerosis Spasticity that is actively recruiting participants, run by Celgene. The registered enrollment target is 200 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT06782490, a Phase 2 study of Multiple Sclerosis Spasticity, is actively recruiting participants, sponsored by Celgene.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-986368
Study Locations (20)
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Local Institution - 0039 - Columbus
- Local Institution - 0069 - Columbus
Victoria
- Box Hill Hospital - Box Hill
- Austin Health - Heidelberg
- The Royal Melbourne Hospital - Parkville
Florida
- Aqualane Clinical Research - Naples
- USF Health - Tampa
New South Wales
- John Hunter Hospital - Newcastle
- University of Sydney - Brain and Mind Research Institute (BMRI) - Sydney
Alabama
- Local Institution - 0033 - Birmingham
Arizona
- Perseverance Research Center,LLC - Scottsdale
Colorado
- Local Institution - 0017 - Aurora
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2027-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06782490
The ClinicalTrials.gov registry entry for NCT06782490 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis Spasticity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06782490 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ohio, Victoria, Florida.
Frequently Asked Questions
What is clinical trial NCT06782490 about?
NCT06782490 is a clinical study titled "A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity". The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
What is the current status of trial NCT06782490?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-06-05. Estimated completion is 2027-06-09.
What conditions does trial NCT06782490 study?
This clinical trial studies the following conditions: Multiple Sclerosis Spasticity.
What interventions are being tested in trial NCT06782490?
The interventions under investigation include: Placebo (DRUG), BMS-986368 (DRUG).
Who is sponsoring clinical trial NCT06782490?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06782490 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.